Lercanidipine 10mg tablets

البلد: المملكة المتحدة

اللغة: الإنجليزية

المصدر: MHRA (Medicines & Healthcare Products Regulatory Agency)

العنصر النشط:

Lercanidipine hydrochloride

متاح من:

Arrow Generics Ltd

ATC رمز:

C08CA13

INN (الاسم الدولي):

Lercanidipine hydrochloride

جرعة:

10mg

الشكل الصيدلاني:

Oral tablet

طريقة التعاطي:

Oral

الفئة:

No Controlled Drug Status

نوع الوصفة الطبية :

Valid as a prescribable product

ملخص المنتج:

BNF: 02060200; GTIN: 5060034834786

نشرة المعلومات

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LERCANIDIPINE HYDROCHLORIDE 10 MG
FILM-COATED TABLETS
LERCANIDIPINE HYDROCHLORIDE 20 MG
FILM-COATED TABLETS
lercanidipine hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU
START USING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your
doctor or pharmacist.
• This medicine has been prescribed for you only.
Do not pass it on to others. It may harm them,
even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
IN THIS LEAFLET:
1. What Lercanidipine Hydrochloride is and what
it is used for
2. What you need to know before you take
Lercanidipine Hydrochloride
3. How to take Lercanidipine Hydrochloride
4. Possible side effects
5. How to store Lercanidipine Hydrochloride
6. Contents of the pack and other information
1. WHAT LERCANIDIPINE HYDROCHLORIDE IS AND WHAT
IT IS USED FOR
Lercanidipine Hydrochloride belongs to a group
of medicines called calcium channel blockers that
block the entry of calcium into the muscle cells of
the heart and the blood vessels that carry blood
away from the heart (the arteries). It is the entry
of calcium into these cells that causes the heart to
contract and arteries to narrow. By blocking the
entry of calcium, calcium channel blockers decrease
contraction of the heart and dilate (widen) the
arteries, and the blood pressure is reduced.
This medicine has been prescribed to you to treat
your high blood pressure, also known
as hypertension.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE
LERCANIDIPINE HYDROCHLORIDE
DO NOT TAKE LERCANIDIPINE HYDROCHLORIDE
• if you are allergic to lercanidipine or to any of the
ingredients in this medicine (listed in section 6)
• if you have had allergic reactions to medicines
that are closely related to lercanidipine (such as
amlodipine, nicardipine,

خصائص المنتج

OBJECT 1
LERCANIDIPINE HYDROCHLORIDE 10 MG FILM-COATED
TABLETS (ARROW)
Summary of Product Characteristics Updated 21-Jan-2014 | Accord-UK Ltd
1. Name of the medicinal product
Lercanidipine hydrochloride 10 mg Film-coated Tablets
2. Qualitative and quantitative composition
One film-coated tablet contains 10 mg lercanidipine hydrochloride,
equivalent to 9.4 mg lercanidipine.
Excipient:
Each lercanidipine hydrochloride 10 mg film-coated tablet contains 30
mg lactose monohydrate.
For a full list of excipients, see section 6.1
3. Pharmaceutical form
Film-coated tablet (tablet).
Yellow, round shaped coated tablet, with bisect on one side and 'LC'
over '
' on the other side.
The score line is only to facilitate breaking for ease of swallowing
and not to divide into equal doses.
4. Clinical particulars
4.1 Therapeutic indications
Lercanidipine hydrochloride 10 mg Film-coated Tablets are indicated
for the treatment of mild to
moderate essential hypertension.
4.2 Posology and method of administration
The recommended dosage is 10 mg once a day to be taken orally at least
15 minutes before a meal; the
dose may be increased to 20 mg depending on the individual patient's
response.
Dose titration should be gradual; it may take 2 weeks before the
maximal antihypertensive effect is
apparent.
Some individuals, not adequately controlled on a single
antihypertensive agent, may benefit from the
addition of lercanidipine to therapy with a beta-adrenoreceptor
blocking drug (atenolol), a diuretic
(hydrochlorothiazide) or an angiotensin converting enzyme inhibitor
(captopril or enalapril).
Since the dose-response curve is steep with a plateau at doses between
20-30 mg, it is unlikely that
efficacy will be improved by higher doses; whereas side effects may
increase.
USE IN THE ELDERLY
Although the pharmacokinetic data and clinical experience suggest that
no adjustment of the daily dosage
is required, special care should be exercised when initiating
treatment in the elderly.
USE IN CHILDREN AND ADOLESCENTS
Lercanidipine is not recommended